west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "受体, G-蛋白偶联" 2 results
  • 视紫红质类及卷曲蛋白受体在糖尿病视网膜病变发生发展中的作用

    鸟苷酸结合蛋白偶联受体(GPCRs)是一类膜受体超家族, 被视为最好的药物靶点。在糖尿病视网膜病变(DR)进程中有大量不同亚型GPCRs参与。其中, 视紫红质类和卷曲蛋白(Frizzled)受体广受关注, 研究方向主要为视网膜炎症反应、新生血管生成、神经元和神经胶质细胞损伤等。血管紧张素Ⅱ受体是最为熟知的视紫红质类受体亚家族。应用血管紧张素Ⅱ受体1拮抗剂可显著降低1型糖尿病患者发生DR的可能性, 但无法减缓已并发DR患者的病变进展; 可减缓并发轻中度DR的2型糖尿病患者的病变进展。其他的视紫红质类受体还有趋化因子受体、大麻素相关受体、GPR91、GPR109A、APJ受体等。Frizzled受体是Wnt信号通路重要的膜受体等。在DR动物模型中, 使用Wnt通路阻断剂Dickkopf homolog 1能改善视网膜炎症、血管渗出、新生血管生成等。但Wnt通路参与DR进展的具体机制有待研究。随着对GPCRs与DR关系了解的加深, 未来将有更多以GPCRs为治疗靶点的药物应用于临床, 为DR患者带来福音。

    Release date: Export PDF Favorites Scan
  • The effects and mechanisms of G protein-coupled receptor 91 on blood-retinal barrier in diabetic rats

    ObjectiveTo investigate the effects and mechanisms of G protein-coupled receptor 91 (GPR91) on blood-retinal barrier (BRB) in diabetic rats. MethodsA lentiviral vector of shRNA targeting rat GPR91 and scrambled shRNA were constructed. Healthy male Sprague-Dawley (SD) rats were selected in this study. The 60 rats were randomized into 4 groups and treated as follows:(1) control group (Group A, n=15), the rats received injections of an equal volume of 0.1% citrate buffer; (2) streptozocin (STZ) group (Group B, n=15), the rats received injections of STZ; (3) LV.shScrambled group (Group C, n=15), diabetic rats received an intravitreal injection of 1 μl 1×108 TU/ml scrambled shRNA lentiviral particles at 2 weeks after the induction of diabetes; (4) LV.shGPR91 group (Group D, n=15), diabetic rats received an intravitreal injection of 1 μl 1×108 TU/ml pGCSIL-GFP-shGPR91 lentiviral particles. At 12 weeks after intravitreal injection, immunohistochemistry and Western blot were used to assess the expression of GPR91, p-extracellular signal-regulated kinase(ERK)1/2, t-ERK1/2, p-Jun N-terminal kinase (JNK), t-JNK, p-p38 mitogen-activated protein kinase (MAPK) and t-p38 MAPK. Haematoxylin and eosin (HE) staining and Evans blue dye were used to assess the structure and function of the retinal vessel. Immunohistochemistry enzyme-linked immunosorbent assay (ELISA) was used to test the protein level of VEGF. ResultsImmunohistochemistry staining showed that GPR91 was predominantly localized to the cell bodies of the ganglion cell layer. Western blot showed that GPR91 expression in Group D decreased significantly compared with Group C (F=39.31, P < 0.01). HE staining showed that the retina tissue in Group B and C developed telangiectatic vessels in the inner layer of retina, while the telangiectatic vessels attenuated in Group D. It was also demonstrated in Evans blue dye that the microvascular leakage in Group D decreased by (33.8±4.11)% compared with Group C and there was significant difference (F=30.35, P < 0.05). The results of ELISA showed the VEGF secretion of Group B and C increased compared with Group A and the VEGF expression in Group D was significantly down regulated after silencing GPR91 gene (F=253.15, P < 0.05).The results of Western blot indicated that compared with Group A, the expressions of p-ERK1/2, p-JNK and p-p38 MAPK were significantly upregulated (q=6.38, 2.94, 3.45;P < 0.05). Meanwhile, the activation of ERK1/2 was inhibited by GPR91 shRNA and the difference was statistically significant (F=22.50, P < 0.05). ConclusionsThe intravitreal injection of GPR91 shRNA attenuated the leakage of BRB in diabetic rats. GPR91 regulated the VEGF release and the leakage of BRB possibly through the ERK1/2 signaling pathway.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content